Know Cancer

or
forgot password

The Potential for Oral DIM Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers


Phase 1
25 Years
45 Years
Open (Enrolling)
Female
Breast Cancer

Thank you

Trial Information

The Potential for Oral DIM Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers


Inclusion Criteria:



- Carriers of a mutation in the BRCA1 gene

- Non-carriers of a mutation in the BRCA1 gene who come from a family with a BRCA1
mutation (a family in which at least one individual has tested positive for a BRCA1
mutation)

- Can participate after being free of DIM supplementation for one month

Exclusion Criteria:

- Have a personal history of cancer

- Currently pregnant or breast-feeding

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science

Outcome Measure:

Oral DIM supplementation increases BRCA1 mRNA expression and hence BRCA1 protein in women with a BRCA1 mutation

Outcome Time Frame:

6 months

Safety Issue:

Yes

Principal Investigator

Steven A Narod, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Women's College Research Institute

Authority:

Canada: Ethics Review Committee

Study ID:

2009-015-B

NCT ID:

NCT01022333

Start Date:

July 2009

Completion Date:

December 2010

Related Keywords:

  • Breast Cancer
  • BRCA1
  • breast cancer
  • 3,3'-di-indolylmethane
  • dietary intervention
  • estrogen metabolites
  • mRNA expression
  • BRCA1 protein
  • Estrogen
  • Breast Neoplasms

Name

Location